- Home
- HROW vs DMLP Comparison
HROW vs DMLP Comparison
Compare HROW & DMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- DMLP
- Stock Information
- Founded
- HROW 1998
- DMLP 2003
- Country
- HROW United States
- DMLP United States
- Employees
- HROW N/A
- DMLP N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- DMLP Oil & Gas Production
- Sector
- HROW Health Care
- DMLP Energy
- Exchange
- HROW Nasdaq
- DMLP Nasdaq
- Market Cap
- HROW 1.4B
- DMLP 1.2B
- IPO Year
- HROW N/A
- DMLP N/A
- Fundamental
- Price
- HROW $45.09
- DMLP $25.61
- Analyst Decision
- HROW Strong Buy
- DMLP
- Analyst Count
- HROW 7
- DMLP 0
- Target Price
- HROW $64.67
- DMLP N/A
- AVG Volume (30 Days)
- HROW 506.9K
- DMLP 99.7K
- Earning Date
- HROW 11-12-2025
- DMLP 10-30-2025
- Dividend Yield
- HROW N/A
- DMLP 12.54%
- EPS Growth
- HROW N/A
- DMLP N/A
- EPS
- HROW N/A
- DMLP 1.71
- Revenue
- HROW $227,661,000.00
- DMLP $161,859,000.00
- Revenue This Year
- HROW $45.86
- DMLP N/A
- Revenue Next Year
- HROW $41.41
- DMLP N/A
- P/E Ratio
- HROW N/A
- DMLP $14.88
- Revenue Growth
- HROW 47.69
- DMLP 4.04
- 52 Week Low
- HROW $20.85
- DMLP $24.01
- 52 Week High
- HROW $59.23
- DMLP $34.88
- Technical
- Relative Strength Index (RSI)
- HROW 74.17
- DMLP 52.91
- Support Level
- HROW $42.23
- DMLP $25.30
- Resistance Level
- HROW $44.07
- DMLP $25.60
- Average True Range (ATR)
- HROW 1.76
- DMLP 0.46
- MACD
- HROW 0.52
- DMLP 0.15
- Stochastic Oscillator
- HROW 98.28
- DMLP 81.35
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.